ULTIMO Ultimovacs ASA


Ultimovacs ASA (ULTIMO) is a pharmaceutical company developing novel immunotherapies against cancer. The lead product candidate is UV1, a therapeutic cancer vaccine inducing a specific T cell response against the universal cancer antigen telomerase. UV1 may serve as a platform for use in combination with other immunotherapy drugs across multiple cancer types. Ultimovacs is performing a development program with clinical trials in Europe and the USA.

Hjemmeside: www.ultimovacs.com